These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10093483)

  • 21. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 22. Ropinirole as compared with levodopa in Parkinson's disease.
    Frucht S
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001686
    [No Abstract]   [Full Text] [Related]  

  • 23. Ropinirole as compared with levodopa in Parkinson's disease.
    Yamamoto T
    N Engl J Med; 2000 Sep; 343(12):884; author reply 885. PubMed ID: 11001685
    [No Abstract]   [Full Text] [Related]  

  • 24. Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias.
    Contin M; Martinelli P; Albani F; Scaglione C; Avoni P; Rizzo G; Baruzzi A
    Clin Neuropharmacol; 2007; 30(2):122-4. PubMed ID: 17414945
    [No Abstract]   [Full Text] [Related]  

  • 25. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 27. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance.
    Ghiglieri V; Picconi B; Calabresi P
    Mov Disord; 2010 Aug; 25(11):1527-9. PubMed ID: 20623774
    [No Abstract]   [Full Text] [Related]  

  • 29. Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
    Lacombe E; Khaindrava V; Melon C; Oueslati A; Kerkerian-Le Goff L; Salin P
    Neurobiol Dis; 2009 Oct; 36(1):116-25. PubMed ID: 19615446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical treatment of levodopa-induced dyskinesias.
    Jankovic J; Lai EC; Krauss J; Grossman R
    Adv Neurol; 1999; 80():603-9. PubMed ID: 10410777
    [No Abstract]   [Full Text] [Related]  

  • 31. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 32. Do on-off variations cause discrepancies in the historical items of the UPDRS?
    Carroll CB; Bain PG
    Mov Disord; 2004 May; 19(5):605. PubMed ID: 15133835
    [No Abstract]   [Full Text] [Related]  

  • 33. Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
    Pouclet H; Derkinderen P; Lebouvier T
    Clin Neurol Neurosurg; 2013 Feb; 115(2):235-6. PubMed ID: 22743235
    [No Abstract]   [Full Text] [Related]  

  • 34. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.
    Blandini F
    Exp Neurol; 2003 Dec; 184(2):556-60. PubMed ID: 14769348
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
    Fiorentini C; Busi C; Spano P; Missale C
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.